BOSTON and PARIS, Oct. 21, 2021("PathMaker"), a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of serious neurological disorders, welcomes John Donoghue, Ph.D. to the Company's Board of Directors. John Donoghue was most recently Founding Director of the Wyss Center for Bio and NeuroEngineering in Geneva, Switzerland where he led the Center's research activities and translational research programs focused on advanced neurotechnology.
"We are incredibly pleased that John Donoghue is joining PathMaker's Board of Directors," said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker. "As a world leader in both fundamental and translational neuroscience, he brings a rare perspective built on institutional leadership, entrepreneurial experience, and neurotechnology device development that will be instrumental as we expand the clinical applications of our proprietary technology platform."
"PathMaker's technology platform has breakthrough potential as a novel therapeutic device. PathMaker has made strong progress and is nearing launch of their first product. I am delighted to be joining the Board of Directors at such a significant time," commented Dr. Donoghue. "The Company's non-invasive approach to treating a wide range of neurological disorders using multi-site neuromodulation leverages decades of progress in neuroscience. It is very exciting to see this technology advance towards market launch. PathMaker's commitment to this innovative therapy promises to improve the lives of millions of people living with disabling neurological disorders."
Prof. Donoghue is an internationally recognized neuroscientist who works at the forefront of neural devices and brain function. He has been Professor of Neuroscience and Engineering at Brown University for over 35 years, where he was the founding Chairman of the Department of Neuroscience and Founder of Brown University's Carney Brain Science Institute. Before becoming the inaugural Director of the Geneva based Wyss Center for Bio- and NeuroEngineering in 2014, he also co-founded Cybernetics Neurotechnology Systems, a pioneering startup in the field of neuroprosthetics that developed the BrainGate brain-computer interface for people with paralysis. Donoghue has authored over 125 scientific publications and is a member of the National Academy of Medicine. His many honors and awards include the Erwin Schroedinger Prize, the Roche-Nature Medicine Prize, the Israel Brain Prize, and the International Prize for Translational Neuroscience.
About PathMaker Neurosystems Inc.
PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of people with serious neurological disorders such as stroke and amyotrophic lateral sclerosis.
Source: PathMaker Neurosystems Inc.
Media contact:
PathMaker PR
